Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan

Rhea-AI Filing Summary

Royalty Pharma plc EVP Marshall Urist reported an open-market sale of 9,098 Class A Ordinary Shares of RPRX at a weighted average price of $55.1843 per share. After this transaction, he directly holds 9,099 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, meaning the trades were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 9,098 shares ($502,067)

Net Sell 1 txn

Insider Urist Marshall

Role EVP, Research & Investments

Sold 9,098 shs ($502K)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	9,098	$55.1843	$502K

Holdings After Transaction: Class A Ordinary Shares — 9,099 shares (Direct, null)

Footnotes (1)

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.77 to $55.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 9,098 shares Weighted average sale price: $55.1843 per share Post-transaction holdings: 9,099 shares +2 more

5 metrics

Shares sold 9,098 shares Class A Ordinary Shares sold in open-market transaction

Weighted average sale price $55.1843 per share Average price across multiple executions

Post-transaction holdings 9,099 shares Directly owned Class A Ordinary Shares after sale

Sale price range $54.77–$55.31 per share Range of individual trade prices in the sale

Net insider direction 9,098 net shares sold transactionSummary netBuySellShares and net-sell direction

Key Terms

Rule 10b5-1 plan, weighted average price, open-market sale, Class A Ordinary Shares

4 terms

Rule 10b5-1 plan financial

"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Ordinary Shares financial

"security_title: Class A Ordinary Shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 05:14 PM Accepted by SEC EDGAR 06/25/2026 - 05:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Urist Marshall

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Research & Investments

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/24/2026		S(1)		9,098	D	$55.1843(2)	9,099	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.77 to $55.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Royalty Pharma (RPRX) report for Marshall Urist?

Royalty Pharma reported that EVP Marshall Urist sold 9,098 Class A Ordinary Shares in an open-market transaction. The weighted average sale price was $55.1843 per share, and the transaction was disclosed in a Form 4 insider trading report.

At what price did the Royalty Pharma EVP sell RPRX shares?

The EVP sold the shares at a weighted average price of $55.1843 per share. Individual trades occurred in a range between $54.77 and $55.31 per share, reflecting multiple executions aggregated into a single reported average price.

How many Royalty Pharma shares does Marshall Urist hold after this Form 4 sale?

After the reported sale, Marshall Urist directly holds 9,099 Class A Ordinary Shares of Royalty Pharma. This figure reflects his direct ownership position immediately following the 9,098-share open-market disposition reported in the Form 4.

Was the Royalty Pharma EVP’s sale under a Rule 10b5-1 trading plan?

Yes. The filing states all reported transactions were effected under a Rule 10b5-1 trading plan adopted on February 12, 2026. Such plans pre-schedule trades, reducing the significance of short-term market timing for these insider sales.

What trading range did Royalty Pharma (RPRX) shares sell at in this insider sale?

The filing explains that individual trades occurred between $54.77 and $55.31 per share. The Form 4 reports a weighted average sale price of $55.1843, aggregating the multiple executions into a single summary price figure.